Larry Oberfeld

Investors, including TPG Growth, Sprout Group, Intel Capital and others, invested more than $120 million in the molecular diagnostics company

Venrock saw a return of 0.6x on its investment

Investors saw a 3.88x return on the $71 million IPO, after the group invested more than $31 million in venture funding

The company, which digital marketing services, generated a 1.14x return on its July 23 IPO

Foundation Capital, Norwest Venture Partners, Sequoia Capital and Storm Ventures saw a total return of 3.23x on their $160 million investment

The drug developer raised more than $213 million in funding prior to its IPO

Alta, Atlas, Greatpoint Ventures, RA Capital Management and Third Rock Ventures invested nearly $160 million in the company, which is developing a treatment for obesity

Investors, including RiverVest, Alta, Novo A/S and others, saw a 3.19x return on their $96 million investemnt

Investors, including Amgen, CMEA and NEA, invested $56 million in the drug developer that focuses on the gastrointestinal tract

The company’s post-offering value was $240 million following its IPO, which was priced at $17 a share